SAN FRANCISCO (Reuters) – The Trump administration’s tax overhaul should accelerate major acquisitions by drugmakers in 2018 after a slow year for deals in 2017, according to senior executives from some of the largest pharmaceutical manufacturers.
Source: Reuters